Evidence map›Paper›PMID 41824275›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

The

Alessandra Guercio, Tess Martin, Silvia Migliari, Anna Gagliardi, Maura Scarlattei, Giorgio Baldari, Nicolas Martelli, Livia Ruffini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alessandra GuercioNuclear Medicine Division, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy. alessandra.guercio@ao.pr.it.ORCID http://orcid.org/0009-0003-6913-8331
Tess MartinPharmacy Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015, Paris, France.ORCID http://orcid.org/0000-0002-1839-4306
Silvia MigliariNuclear Medicine Division, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy.ORCID http://orcid.org/0000-0002-2082-773X
Anna GagliardiNuclear Medicine Division, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy.ORCID http://orcid.org/0009-0006-8840-385X
Maura ScarlatteiNuclear Medicine Division, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy.ORCID http://orcid.org/0000-0002-2039-3345
Giorgio BaldariNuclear Medicine Division, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy.ORCID http://orcid.org/0000-0002-8634-2890
Nicolas MartelliPharmacy Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015, Paris, France.ORCID http://orcid.org/0000-0001-5959-231X
Livia RuffiniNuclear Medicine Division, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy.ORCID http://orcid.org/0000-0002-4398-8368

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSustainability in healthcare, particularly Nuclear Medicine, is essential, especially in managing radioactive materials. Traditional centralized production of Fluorine-18 tracers for PET imaging faces challenges like transport logistics, decay losses and supply chain vulnerabilities. Decentralized production with radionuclide generators, such as the Germanium-68/Gallium-68 (

resultsBetween 2016 and 2024, 416 batches of

conclusionsThe

Indexed as

68Ge/68Ga generatorCost-analysisRadiopharmaceutical productionSustainabilityWorkflow efficiency

Identifiers

PMID41824275
PMCPMC13096388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.